Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS 1.5/30 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Oral contraception
Prevention of pregnancy
One tablet orally once daily at the same time each day.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinylestradiol: terminal half-life 13-17 hours (mean 15 h). Desogestrel active metabolite 3-keto-desogestrel: terminal half-life 23-28 hours (mean 25 h). Clinical: steady-state achieved by cycle day 7-10; missed pill instructions based on half-life.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol undergoes first-pass metabolism in gut wall and liver via CYP3A4; desogestrel is metabolized by CYP2C9 and CYP2C19 to active metabolite etonogestrel.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: ~55-60% as ethinylestradiol glucuronide and sulfate conjugates; ~40% as desogestrel metabolites (largely as 3-keto-desogestrel glucuronide). Fecal: ~30-35% of desogestrel metabolites; <5% for ethinylestradiol. Biliary: minor for both.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinylestradiol: ~97% bound to albumin (90%) and SHBG (minor). 3-Keto-desogestrel: ~95% bound: albumin (65%) and SHBG (30%).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinylestradiol: Vd ~2.5-3.0 L/kg; distributes extensively into body tissues (breast, liver). 3-Keto-desogestrel: Vd ~1.5-2.0 L/kg; moderate tissue binding.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: ethinylestradiol ~40-50% (due to first-pass metabolism); desogestrel ~76% (≥60% converted to active 3-keto-desogestrel after first pass).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
Contraindicated in patients with renal impairment (e GFR <60 m L/min/1.73 m2) due to increased risk of hyperkalemia and reduced efficacy.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) due to impaired hormone metabolism and potential for adverse effects.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use in pediatric patients. Safety and efficacy have not been established in females under 18 years of age.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. Efficacy in women over 40 years of age has not been fully established; consider alternative contraception due to increased cardiovascular risk.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and smoking intensity (especially in women over 35).
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders (e.g., DVT, PE),Myocardial infarction and stroke risk,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Ocular lesions,Dose-related risk of VTE from desogestrel-containing pills
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders,History of DVT or PE,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Hepatic adenoma or carcinoma,Active liver disease with abnormal function
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food restrictions. Grapefruit juice does not significantly interact with ethinylestradiol or gestodene. St. John's Wort (Hypericum perforatum) reduces contraceptive efficacy by inducing CYP3A4 metabolism; avoid concurrent use. High-fat meals may increase ethinylestradiol absorption slightly but no dose adjustment needed.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester: Combination oral contraceptives are not associated with a major increase in risk of birth defects. Second and third trimesters: Prolonged use may be associated with fetal harm including cardiovascular and skeletal anomalies, though data are limited. Known pregnancy contraindicates use.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Ethinyl estradiol and levonorgestrel are excreted in breast milk in small amounts. M/P ratio not established. Potential for adverse effects in nursing infant, including reduced milk production and jaundice. Use not recommended in breastfeeding women.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy. No dose adjustments applicable; use should be discontinued immediately if pregnancy occurs.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
GILDESS 1.5/30 is a combined oral contraceptive (COC) containing ethinylestradiol 30 µg and gestodene 75 µg. Gestodene is a third-generation progestin with high progestogenic activity and low androgenic effects, reducing acne and hirsutism. This formulation has a higher risk of venous thromboembolism (VTE) compared to second-generation COCs. Avoid in women with migraines with aura, hypertension (BP >160/100), or BMI >30 due to increased VTE risk. For missed pills: if one pill is missed, take it as soon as remembered and continue; if two or more pills are missed, take the last missed pill, use backup contraception for 7 days, and consider emergency contraception if unprotected intercourse occurred.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time, preferably in the evening, to reduce nausea.,If you miss a pill, follow the instructions in the package leaflet; if you miss more than one pill, use additional contraception (e.g., condoms) for 7 days.,Smoking increases the risk of serious cardiovascular side effects; do not smoke while taking this medication, especially if you are over 35.,Tell your doctor if you experience severe headache, chest pain, leg pain or swelling, visual disturbances, or jaundice.,This medication does not protect against sexually transmitted infections; use condoms for additional protection.,Vomiting or severe diarrhea within 4 hours of taking the pill reduces efficacy; consider it as a missed pill and use backup contraception.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS 1.5/30 vs ALYACEN 7/7/7, answered by our medical review team.
GILDESS 1.5/30 is a Oral Contraceptive that works by Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS 1.5/30 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS 1.5/30 is: One tablet orally once daily at the same time each day.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS 1.5/30 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS 1.5/30 is classified as Category C. First trimester: Combination oral contraceptives are not associated with a major increase in risk of birth defects. Second and third trimesters: Prolonged use may be associated wit. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.